Correvio Pharma Corp (COM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Correvio Pharma Corp (COM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10078
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:66
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). Correvio has collaborations with other pharmaceutical companies to commercialize its products. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.

Correvio Pharma Corp (COM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Evotec and Artesian Therapeutics Enter into Agreement 13
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25
Licensing Agreements 26
ZAO Firma Enters into Licensing Agreement with Correvio 26
Correvio International Enters into Licensing Agreement with ATCO Laboratories 27
Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30
Eddingpharm Enters into Licensing Agreement with Correvio International 31
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32
Equity Offering 33
Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33
Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39
Cardiome Pharma Completes Public Offering Of Shares For Us$13.7 Million 41
Acquisition 43
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46
Correvio Pharma Corp – Key Competitors 47
Correvio Pharma Corp – Key Employees 48
Correvio Pharma Corp – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Aug 14, 2018: Correvio announces second quarter 2018 financial results 50
May 15, 2018: Correvio Announces First Quarter 2018 Financial Results 52
Mar 13, 2018: Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results 54
Nov 14, 2017: Cardiome Reports Third Quarter 2017 Financial Results 56
Aug 08, 2017: Cardiome Reports Second Quarter 2017 Financial Results 58
May 15, 2017: Cardiome Reports First Quarter 2017 Financial Results 60
Mar 07, 2017: Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results 61
Corporate Communications 63
May 16, 2017: Cardiome Reports Changes To Senior Management Team 63
Other Significant Developments 64
May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV 64
May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Evotec and Artesian Therapeutics Enter into Agreement 13
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25
ZAO Firma Enters into Licensing Agreement with Correvio 26
Correvio International Enters into Licensing Agreement with ATCO Laboratories 27
Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30
Eddingpharm Enters into Licensing Agreement with Correvio International 31
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32
Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33
Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39
Cardiome Pharma Completes Public Offering Of Shares For Us$13.7 Million 41
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46
Correvio Pharma Corp, Key Competitors 47
Correvio Pharma Corp, Key Employees 48
Correvio Pharma Corp, Subsidiaries 49

List of Figures
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Correvio Pharma Corp (COM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • St. James’S Place Plc:企業の戦略・SWOT・財務分析
    St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report Summary St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Catholic University of Leuven:製薬・医療:M&Aディール及び事業提携情報
    Summary Catholic University of Leuven (KU Leuven) is a scientific research and educational service provider that provides bachelors degree, post graduate degree and doctorate degree programs. The university provides educational courses in the areas of psychology and educational sciences, arts, law, …
  • Vinnolit GmbH & Co KG:企業の戦略的SWOT分析
    Vinnolit GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Oil India Limited:企業の戦略・SWOT・財務分析
    Oil India Limited - Strategy, SWOT and Corporate Finance Report Summary Oil India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Pets at Home Group Plc (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Group Plc (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Chongqing Taiji Industry (Group) Co Ltd (600129):製薬・医療:M&Aディール及び事業提携情報
    Summary Chongqing Taiji Industry (Group) Co Ltd (Chongqing Taiji) is a provider of generic products. The company offers products such as traditional Chinese medicine, hospital products, OTC products, base products, and dietary supplement. It provides research and development, equipment, and manageme …
  • CGU Insurance Ltd:企業の戦略・SWOT・財務分析
    CGU Insurance Ltd - Strategy, SWOT and Corporate Finance Report Summary CGU Insurance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Taiwan Semiconductor Manufacturing Company Limited:企業のM&A・事業提携・投資動向
    Taiwan Semiconductor Manufacturing Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Taiwan Semiconductor Manufacturing Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business de …
  • Janssen Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Janssen Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Janssen Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Bristol-Myers Squibb Co (BMY):企業の財務・戦略的SWOT分析
    Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Arup Group Ltd:企業の戦略的SWOT分析
    Arup Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • BrainLAB AG:医療機器:M&Aディール及び事業提携情報
    Summary BrainLAB AG (Brainlab) is a medical technology company that develops, manufactures and markets medical technology facilitated by software that helps optimize treatment outcomes. The company provides technological solutions in radiosurgery and numerous surgical fields such as neurosurgery, or …
  • Cheniere Energy Inc (LNG):企業の財務・戦略的SWOT分析
    Cheniere Energy Inc (LNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • U.S. Department of Health and Human Services-製薬・医療分野:企業M&A・提携分析
    Summary U.S. Department of Health and Human Services (HHS) is a healthcare service provider that offers patient care and support services. The organization’s service areas include health insurance marketplace, mental health, food safety, fighting HIV or AIDS, supporting military families, statistics …
  • iPass Inc. (IPAS):企業の財務・戦略的SWOT分析
    iPass Inc. (IPAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Pear Therapeutics Inc:企業の製品パイプライン分析2018
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Motus Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Motus Therapeutics Inc (Motus), formerly Rhythm Pharmaceuticals, Inc. is a subsidiary of Rhythm Holding Company LLC, biotechnology company that provides therapies. The company develops peptide therapeutics for the treatment of metabolic diseases. Its products under clinical development inclu …
  • DiaSys Diagnostic Systems GmbH:医療機器:M&Aディール及び事業提携情報
    Summary DiaSys Diagnostic Systems GmbH (DiaSys Diagnostic) is a developer, manufacturer and marketer of point of care diagnostic products. The company’s products include automated analyzers, calibrators or controls, POCT systems and tests, reagents, system kits and OEM products. It provides automate …
  • SP Transmission plc:企業の戦略的SWOT分析
    SP Transmission plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Smerud Medical Research International AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Smerud Medical Research International AS (Smerud Medical) is a contract research organization that offers drug development services. The company conducts clinical trials to the pharmaceutical and biotechnology companies for improving new medical compounds. It provides services such as clinic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆